Gastroenterology
Landos Biopharma Inc. focuses on ulcerative colitis, with clinical research centered on inflammatory disease affecting the gastrointestinal tract and the management of moderate to severe disease activity.
- Ulcerative colitis
- Inflammatory bowel disease
- Gastrointestinal inflammation
The sponsor’s active research network spans multiple collaborating sites across several countries, reflecting a therapeutic interest in immune-mediated bowel disease and related clinical outcomes.
Immunology
Its clinical program addresses immune-driven intestinal inflammation, with attention to disease control in patients experiencing persistent mucosal and systemic inflammatory activity.
- Immune-mediated inflammation
- Mucosal immunity
- Inflammatory disease biology
Research activity in this area is aligned with therapeutic development for conditions where immune regulation is central to symptom burden and disease progression.
Therapeutic Development
The sponsor is engaged in clinical evaluation of an oral investigational therapy for moderate to severe ulcerative colitis, with interest in treatment effects on disease activity and tolerability.
- Oral therapy
- Clinical activity
- Safety evaluation
This area reflects a focus on advancing treatment options for patients requiring ongoing management of chronic inflammatory bowel disease.
Inflammatory Disease Research
Clinical interest extends to the broader study of chronic inflammation and its impact on bowel function, symptom persistence, and disease severity in ulcerative colitis.
- Chronic inflammation
- Disease severity
- Symptom control
The research footprint includes active recruitment across multiple sites, supporting investigation of therapies for patients with significant inflammatory burden.
